Bloomage BioTechnology Corporation Limited's (SHSE:688363) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Bloomage BioTechnology Corporation Limited's (SHSE:688363) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Bloomage BioTechnology (SHSE:688363) has had a rough three months with its share price down 21%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. Particularly, we will be paying attention to Bloomage BioTechnology's ROE today.
Bloomage Biotechnology(上海證券交易所代碼:688363)經歷了艱難的三個月,其股價下跌了21%。但是,仔細觀察其良好的財務狀況可能會讓你重新考慮。鑑於基本面通常會推動長期市場業績,該公司值得關注。特別是,我們今天將關注Bloomage Biotechnology的投資回報率。
Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
股本回報率或投資回報率是用於評估公司管理層利用公司資本效率的關鍵指標。簡而言之,投資回報率顯示了每美元從其股東投資中產生的利潤。
How To Calculate Return On Equity?
如何計算股本回報率?
The formula for return on equity is:
股本回報率的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回報率 = 淨利潤(來自持續經營業務)÷ 股東權益
So, based on the above formula, the ROE for Bloomage BioTechnology is:
因此,根據上述公式,Bloomage BioTechnology的投資回報率爲:
11% = CN¥801m ÷ CN¥7.0b (Based on the trailing twelve months to September 2023).
11% = 8.01億元人民幣 ¥70億元人民幣(基於截至2023年9月的過去十二個月)。
The 'return' is the profit over the last twelve months. Another way to think of that is that for every CN¥1 worth of equity, the company was able to earn CN¥0.11 in profit.
“回報” 是過去十二個月的利潤。另一種看法是,每持有價值1元人民幣的股權,公司就能獲得0.11元人民幣的利潤。
What Is The Relationship Between ROE And Earnings Growth?
投資回報率與收益增長之間有什麼關係?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
我們已經確定,投資回報率是衡量公司未來收益的有效盈利指標。然後,我們能夠評估公司的收益增長潛力,具體取決於公司對這些利潤進行再投資或 “保留” 了多少及其有效性。假設其他一切保持不變,那麼與不一定具有這些特徵的公司相比,投資回報率和利潤保留率越高,公司的增長率就越高。
Bloomage BioTechnology's Earnings Growth And 11% ROE
布魯瑪生物科技的收益增長和11%的投資回報率
To start with, Bloomage BioTechnology's ROE looks acceptable. On comparing with the average industry ROE of 6.6% the company's ROE looks pretty remarkable. Probably as a result of this, Bloomage BioTechnology was able to see a decent growth of 16% over the last five years.
首先,彭博生物技術的投資回報率似乎是可以接受的。與6.6%的行業平均投資回報率相比,該公司的投資回報率看起來相當可觀。可能是由於這個原因,Bloomage Biotechnology得以在過去五年中實現了16%的可觀增長。
As a next step, we compared Bloomage BioTechnology's net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 11%.
下一步,我們將Bloomage Biotechnology的淨收入增長與該行業進行了比較,令人高興的是,我們發現該公司的增長高於11%的行業平均增長。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240221/0-d8bc32ea89062407c5adf213a14e3082-0-f4f890d42af1eac8276445d37a05b2e1.png/big)
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. Doing so will help them establish if the stock's future looks promising or ominous. Is Bloomage BioTechnology fairly valued compared to other companies? These 3 valuation measures might help you decide.
爲公司附加價值的基礎在很大程度上與其收益增長息息相關。無論如何,投資者應設法確定預期的收益增長或下降是否已計入其中。這樣做將幫助他們確定股票的未來是樂觀還是不祥的。與其他公司相比,Bloomage 生物技術的估值是否合理?這3種估值指標可能會幫助您做出決定。
Is Bloomage BioTechnology Using Its Retained Earnings Effectively?
Bloomage BioTechnology是否有效地利用了
Bloomage BioTechnology has a healthy combination of a moderate three-year median payout ratio of 29% (or a retention ratio of 71%) and a respectable amount of growth in earnings as we saw above, meaning that the company has been making efficient use of its profits.
Bloomage Biotechnology的三年派息率中位數爲29%(或71%的留存率)和可觀的收益增長(如上所示),這是一個健康的組合,這意味着該公司一直在有效利用其利潤。
Moreover, Bloomage BioTechnology is determined to keep sharing its profits with shareholders which we infer from its long history of four years of paying a dividend. Based on the latest analysts' estimates, we found that the company's future payout ratio over the next three years is expected to hold steady at 28%. Still, forecasts suggest that Bloomage BioTechnology's future ROE will rise to 15% even though the the company's payout ratio is not expected to change by much.
此外,Bloomage Biotechnology決心繼續與股東分享利潤,這是我們從其四年支付股息的長期歷史中推斷出來的。根據分析師的最新估計,我們發現該公司未來三年的派息率預計將穩定在28%。儘管如此,預測表明,Bloomage Biotechnology的未來投資回報率將升至15%,儘管該公司的派息率預計不會有太大變化。
Conclusion
結論
On the whole, we feel that Bloomage BioTechnology's performance has been quite good. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.
總的來說,我們認爲Bloomage Biotechnology的表現相當不錯。具體而言,我們喜歡該公司以高回報率再投資其利潤的很大一部分。當然,這導致該公司的收益大幅增長。既然如此,分析師的最新預測顯示,該公司的收益將繼續擴大。這些分析師的預期是基於對該行業的廣泛預期,還是基於公司的基本面?點擊此處進入我們分析師對公司的預測頁面。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。